These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18222982)

  • 1. Comment on: The pharmacogenetics of methotrexate.
    van der Kooij SM; Wessels JA; Huizinga TW; Guchelaar HJ
    Rheumatology (Oxford); 2008 Apr; 47(4):557; author reply 5557-8. PubMed ID: 18222982
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
    Dervieux T
    J Rheumatol; 2008 Apr; 35(4):550-2. PubMed ID: 18398948
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate.
    Kooloos WM; Guchelaar HJ; Huizinga TW; Wessels JA
    Rheumatology (Oxford); 2009 Sep; 48(9):1176-7; author reply 1177. PubMed ID: 19602477
    [No Abstract]   [Full Text] [Related]  

  • 4. Race and methotrexate pharmacogenetics in rheumatoid arthritis.
    Ranganathan P; McLeod H
    J Rheumatol; 2010 May; 37(5):1064; author reply 1065. PubMed ID: 20439524
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway.
    Grabar PB; Rojko S; Logar D; Dolzan V
    Ann Rheum Dis; 2010 May; 69(5):931-2. PubMed ID: 20413572
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al.
    Riksen NP; Rongen GA; Smits P; van Riel P; Barrera P
    Arthritis Rheum; 2007 Feb; 56(2):694; author reply 694-5. PubMed ID: 17265507
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmacogenetics of methotrexate.
    Hider SL; Bruce IN; Thomson W
    Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort.
    Owen SA; Lunt M; Hider SL; Bruce IN; Barton A; Thomson W
    Arthritis Rheum; 2010 Dec; 62(12):3827-9. PubMed ID: 20848569
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability.
    Beretta L
    Rheumatology (Oxford); 2009 Dec; 48(12):1619-20; author reply 1620. PubMed ID: 19828599
    [No Abstract]   [Full Text] [Related]  

  • 10. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?
    Bansard C; Lequerré T; Daveau M; Boyer O; Tron F; Salier JP; Vittecoq O; Le-Loët X
    Rheumatology (Oxford); 2009 Sep; 48(9):1021-8. PubMed ID: 19483089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond.
    Kooloos WM; Wessels JA; van der Kooij SM; Allaart CF; Huizinga TW; Guchelaar HJ
    Ann Rheum Dis; 2009 Aug; 68(8):1371. PubMed ID: 19605746
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of methotrexate effects and single-nucleotide polymorphisms in the folate pathway in rheumatoid arthritis: comment on the article by Wessels et al.
    Ranganathan P
    Arthritis Rheum; 2006 Oct; 54(10):3372; author reply 3372-3. PubMed ID: 17009311
    [No Abstract]   [Full Text] [Related]  

  • 13. Do snapshot statistics fool us in MTX pharmacogenetic studies in arthritis research?
    de Rotte MC; Luime JJ; Bulatovic M; Hazes JM; Wulffraat NM; de Jonge R
    Rheumatology (Oxford); 2010 Jun; 49(6):1200-1. PubMed ID: 20110251
    [No Abstract]   [Full Text] [Related]  

  • 14. In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment.
    Baricordi OR; Govoni M; Rizzo R; Trotta F
    Ann Rheum Dis; 2007 Aug; 66(8):1125-6. PubMed ID: 17626975
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacogenomics of methrotexate: a strategy for a customized therapeutic scheme for patients with rheumatoid arthritis].
    Mena-Ramírez JP; Salazar-Páramo M; Dávalos-Rodríguez IP
    Gac Med Mex; 2008; 144(5):449-51. PubMed ID: 19043967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identity of single-nucleotide polymorphisms used in a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy: comment on the article by Wessels et al.
    Warren RB; Gibbons LJ
    Arthritis Rheum; 2008 Apr; 58(4):1204-5; author reply 1205. PubMed ID: 18383387
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
    Taniguchi A; Kamatani N
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():686-90. PubMed ID: 15799443
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by Khanna et al.
    Morgan SL; Baggott JE; Alarcón GS
    Arthritis Rheum; 2006 May; 54(5):1708-9; author reply 1709-10. PubMed ID: 16646062
    [No Abstract]   [Full Text] [Related]  

  • 20. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis.
    Ranganathan P; McLeod HL
    Arthritis Rheum; 2006 May; 54(5):1366-77. PubMed ID: 16645965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.